Dupixent - Yahoo Search Results

Ads
related to: Dupixent
HCP: DUPIXENT® (dupilumab) - Official HCP Website

www.dupixenthcp.com
Want To Enroll Your Patients Today? Learn How To Get Started w/ DUPIXENT MyWay®. View Instructions For Use And Prescribing Information For DUPIXENT® (dupilumab) Today.
Dosing & Administration · Dupixent MyWay® · Getting Started · Trial Results
FAQs
Find Answers To Your Questions

& Understand Treatment Now

Patient Access Support
Support For Patients Today

Enroll In Dupixent MyWay

Getting Started
Learn More About Dosing Schedules

Find Answers To Your Questions

Resources
Access Support For Patients

Download Resources Today
DUPIXENT® (dupilumab) - Official Patient Website

www.dupixent.com
Discover What's Possible With DUPIXENT® (dupilumab): Visit The Official Patient Site Now! Learn About FDA Approved Rx DUPIXENT® (dupilumab). Visit The Official Site For More Info.
Instructions For Use · Injection Support · Safety Information · Prescribing Information
Service catalog: Copay Card, Patient Education, Prescribing Info, Safety Information

Search results

- ASLAN expands research on atopic dermatitis treatment By Investing.com
  Investing.com· 1 day ago
  ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage biopharmaceutical company, has announced a new...
- Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript
  Insider Monkey via Yahoo Finance· 7 hours ago
  Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript May 3, 2024 Kymera...
- Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
  Zacks via Yahoo Finance· 9 hours ago
  Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the...
- Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
  Zacks via Yahoo Finance· 1 day ago
  Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the...
- Earnings call: Kymera Therapeutics reports progress in drug development By Investing.com
  Investing.com· 11 hours ago
  Kymera Therapeutics, during their first quarter 2024 earnings call, provided a comprehensive update...
- 11 Oversold Growth Stocks to Buy Right Now
  Insider Monkey via Yahoo Finance· 5 days ago
  In this article, we will take a look at the 11 oversold growth stocks to buy right now. To skip our analysis of the recent trends and market activity,...
- Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
  Zacks via Yahoo Finance· 4 days ago
  Evaluate the expected performance of Regeneron (REGN) for the quarter ended March 2024, looking...
- Small Business - The Andalusia Star-News | The Andalusia Star-News
  The Andalusia Star-News· 2 days ago
  First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first